Mugotussol

Quick links to important sections

Mugotussol

Treatment option: Cough

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Mugotussol

Property Description
Active ingredient Dextromethorphan Hydrobromide
Form Syrup, Solution, Tablet, Capsule
Pharmacological class Antitussive agent (Cough suppressant)
Common purpose Relief from dry, non-productive coughing
Origin Synthetic analogue

Mugotussol: Classification and Identity of the Antitussive Agent

Mugotussol is an oral pharmaceutical preparation known for its use as a cough suppressant, aligning with the pharmacological class of Antitussive agents. The single active ingredient is Dextromethorphan Hydrobromide, a key compound recognized for its clinical action in alleviating cough. The medicine is often positioned for Over-The-Counter (OTC) access, offering a means of self-management for acute symptoms. It is frequently available in multiple dosage forms—including syrup, solution, tablet, and capsule—for oral route of administration.

Composition and Origin: The Dextromethorphan Profile

The active substance, Dextromethorphan Hydrobromide, is structurally defined as a synthetic analogue of a compound from the morphinan family, yet it is classified as a non-opioid cough suppressant due to its specific pharmacological profile at antitussive doses. As a single-ingredient product, Mugotussol focuses its formulation exclusively on the cough-suppressing molecule. For liquid presentations, the active compound is combined with an aqueous vehicle or a simple syrup base for liquids, while solid forms utilize specialized pharmaceutical excipients.

The General Purpose of Mugotussol

The overarching purpose of Mugotussol is to provide targeted relief from disruptive, dry, or non-productive coughing, such as the persistent irritation associated with minor bronchial issues. The medicine works by influencing the medullary cough center in the brainstem, which raises the cough threshold. Dextromethorphan is effective for temporarily relieving cough caused by minor throat and bronchial irritation. This cough suppressant mechanism offers specialized relief by reducing the intensity of the involuntary reflex, differing functionally from expectorants designed to aid mucus clearance.

Regulatory References

  1. NIH: Dextromethorphan Drug Information

What side effects are possible with Mugotussol?

Possible Side Effects and Safety Information

The safety profile of Mugotussol, which contains the active ingredient Dextromethorphan Hydrobromide, is officially documented by government health authorities, classifying potential adverse reactions by frequency and physiological system. The most commonly documented effects are related to the Nervous System and Gastrointestinal System.


Adverse Reaction Classification

Classification Examples of Officially Listed Effects
Common Drowsiness, Dizziness, Nausea, Vomiting, Stomach Discomfort.
Rare Severe Allergic Reactions (Anaphylaxis/Hypersensitivity).
Frequency Not Known Mental Confusion, Excitement (especially noted in children).

Serious Adverse Reactions and Key Constraints

Regulatory documents highlight a serious adverse reaction risk, notably Serotonin Syndrome. This life-threatening condition is strongly associated with the co-administration of Dextromethorphan with Monoamine Oxidase Inhibitors (MAOIs), leading to a strict contraindication against concurrent use or use within 14 days of stopping an MAOI.

Official labeling also defines population-specific safety considerations. Use is constrained in individuals with severe hepatic impairment due to the potential for increased drug exposure and effects. Additionally, caution is advised for patients with certain chronic respiratory diseases or persistent coughs associated with pulmonary conditions, unless otherwise specified in official directions.

Overdose and Emergency Response

Mugotussol overdose, involving the active ingredient Dextromethorphan Hydrobromide, primarily manifests through central nervous system (CNS) and neuromuscular toxicity. Documented clinical signs in overdose include severe drowsiness, confusion, unusual excitement or agitation, and involuntary muscular movements such as nystagmus, ataxia, dystonia, and muscular rigidity. Systemic effects can involve tachycardia (rapid heartbeat) and elevated body temperature (hyperthermia), alongside severe nausea and vomiting.

Overdose is classified as a condition that may lead to life-threatening severe outcomes. These include progression to coma, seizures, and severe respiratory depression leading to apnea, which is particularly noted in young children. A critical, documented risk, especially when the substance is taken at high doses, is the development of Serotonin Syndrome.

The official regulatory response mandates that quick medical attention is critical. Individuals must seek immediate medical attention or contact a Poison Control Center right away, as manifestations exceeding mild effects require prompt emergency referral. Management is explicitly defined as symptomatic and supportive care, including continuous monitoring of vital signs and, in certain cases, the administration of activated charcoal as an initial procedural step.

Therapeutic Uses of Mugotussol

What Mugotussol Treats: Main Uses and Benefits

Mugotussol is commonly used to help manage symptoms of a dry, non-productive cough—a type of cough characterized by a frequent, irritating tickling sensation. The medicine is primarily applied in contexts where additional symptomatic support is needed to address the distress caused by persistent, unproductive episodes, often linked to the common cold, flu, or minor respiratory irritation. The active component is relevant for easing symptoms associated with minor throat and bronchial irritation.

The medicine is relevant for easing symptoms that interfere with daily functioning, especially at night. It helps address symptom clusters that may become intense or disruptive, contributing to improved comfort during periods of heightened symptoms and providing supportive relief when symptoms interfere with routine activities.

“The medicine is used for the symptomatic relief of dry, irritating coughs associated with acute episodes.”


Quick Fact: Supports Relief for Dry and Irritating Cough

The medicine is commonly used across conditions characterized by episodic or acute symptom patterns.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Eligibility Scope

Populations for whom use is allowed (as stated in label):

  • Adults 18 years of age and older.
  • Children 12 years of age and older.
  • Children 6 to 12 years of age, under specific labeled directions.

Populations for whom use is contraindicated (Absolute Prohibition):

  • Patients currently taking a Monoamine Oxidase Inhibitor (MAOI) or who have discontinued MAOI therapy within the preceding 14 days.
  • Patients with known hypersensitivity to dextromethorphan or any of the product's excipients.

Age-Related and Conditional Eligibility Rules

Classification Rule Applicable Populations
Prohibited OTC Use The medicine is not for over-the-counter use in children under 4 years of age. Infants and children under 4 years
Restricted Use Not recommended for persistent or chronic cough (e.g., associated with smoking, asthma) or cough with excessive secretions unless advised by a healthcare professional. Patients with chronic respiratory conditions
Conditional Use Pregnancy and Lactation status advises individuals to consult a health professional before use. Specific formulations containing alcohol must be avoided while nursing. Pregnant or breastfeeding individuals
Comorbidity Use may be contraindicated for individuals with Phenylketonuria (PKU) if the specific product contains aspartame. Patients with PKU (Formulation-dependent)

Connection to the Overall Eligibility Profile

Official regulatory documents define strict boundaries for the use of Mugotussol, establishing who can and cannot use the medicine based on safety-critical criteria. Absolute contraindications, such as the use of MAOIs, prohibit eligibility entirely. Furthermore, age-related restrictions limit OTC use below 4 years, and eligibility is conditional on the type of cough, as the product is explicitly labeled as not recommended for chronic or productive symptoms.

What should I know about interactions with other medicines?

The official regulatory profile for Mugotussol (Dextromethorphan) details clinically significant interactions across both pharmacokinetic (PK) and pharmacodynamic (PD) pathways.

Category Official Interaction Documentation Summary
Contraindicated Combinations Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is contraindicated due to the risk of a serious drug-drug interaction (Serotonin Syndrome). A mandatory 14-day washout period is required after discontinuing an MAOI before Dextromethorphan can be administered.
Exposure-Modifying Interactions Potent CYP2D6 Inhibitors (e.g., Quinidine, Fluoxetine, Bupropion) significantly increase the plasma concentration of Dextromethorphan by inhibiting its metabolic clearance. This PK interaction leads to substantially higher systemic exposure. This effect is also noted in individuals classified as CYP2D6 Poor Metabolizers.
Additive Pharmacodynamic Effects The combination with other Serotonergic Agents (including SSRIs, SNRIs, and the herbal product St. John's Wort) increases the risk of Serotonin Syndrome. Furthermore, co-administration with Alcohol (Ethanol) and other Central Nervous System (CNS) depressants may result in additive CNS depression.

Official Interaction Statements:

  • Co-administration with MAOIs is prohibited due to the risk of Serotonin Syndrome, requiring a 14-day separation period.
  • The use of potent CYP2D6 inhibitors elevates Dextromethorphan exposure by inhibiting its metabolic clearance.
  • The risk of Serotonin Syndrome is increased when combined with other serotonergic medicines.
  • Additive CNS depression is a documented outcome when co-administered with alcohol or other CNS depressants.

Connection to the overall interaction profile: Regulatory documents structure the product's interaction profile around prohibiting highly severe pharmacodynamic risks (MAOIs) and managing pharmacokinetic risks associated with the CYP2D6 metabolic pathway, which dictates exposure-altering interactions. This provides clear restrictions on combined use and identifies specific substance categories requiring caution.

Mechanism of Action

Mugotussol's mechanism of action is mediated by its active component, dextromethorphan. This lipophilic molecule crosses the blood-brain barrier to exert central effects. Its primary biological targets include the sigma1 receptor, where it acts as an agonist, and the N-methyl-D-aspartate (NMDA) receptor, functioning as a non-competitive antagonist.

At the sigma1 receptor, dextromethorphan modulates various intracellular signaling pathways, contributing to the central nervous system effects. Furthermore, the parent drug and its metabolite, dextrorphan, bind within the ion channel of the NMDA receptor, preventing ion flux and altering glutamatergic neurotransmission in the central nervous system, particularly within the medullary cough center. The combination of sigma1 receptor agonism and NMDA receptor antagonism results in a modulation of the excitability of afferent neural pathways involved in the cough reflex arc. This downstream cascade leads to an elevated threshold for the activation of the central cough center, culminating in a reduction of efferent signaling to the respiratory musculature.

Dosage and Administration Information

How to Use Mugotussol: Official Administration Guidelines

This section outlines the usage instructions for medicine containing Dextromethorphan (as found in Mugotussol-type products), regarding the standardized application for antitussive agents.

Administration Scope

The approved route of administration for this medicine is Oral. It can typically be taken with or without food, as no specific timing relative to meals is mandated in the product specifications.

Official Dosing and Frequency

Age Group Single Dose Range Dosing Frequency
Adults and Children 12+ years 10 mg to 30 mg Every 4 to 8 hours
Children 6 to under 12 years 5 mg to 10 mg Every 4 to 8 hours
Children 4 to under 6 years 2.5 mg to 5 mg Every 4 to 8 hours

Do not exceed four to six doses in a 24-hour period, depending on the specific maximum dose defined on the product label. Mugotussol-type products are generally not recommended for children under 4 years for over-the-counter use.

Preparation and Procedural Steps

  1. Measure Accurately: For liquid forms (syrups or solutions), use an accurate, calibrated measuring device (such as a dosing cup or oral syringe) to measure the prescribed dose precisely. Do not use a household teaspoon.
  2. Administer Orally: Swallow the measured dose of liquid or the whole tablet/capsule.
  3. Duration Constraint: The medicine should only be used for the shortest duration necessary to address symptoms. Stop use and consult a healthcare professional if the condition lasts more than 7 days or if symptoms worsen.

Missed Dose Instructions

If a dose is missed, take it when remembered. If it is almost time for the next scheduled dose, skip the missed dose and resume the regular dosing schedule. Do not take a double dose to make up for a missed one.

Recent Clinical Evidence

Research evidence / Overview of studies for Mugotussol

Evidence for Use in Acute, Non-Productive Cough

Research on Dextromethorphan (the active ingredient in Mugotussol) has been conducted using several designs, primarily Randomized Controlled Trials (RCTs) and systematic reviews. These short-term studies were applied in trials assessing episodic symptom patterns in adults and children with an acute, non-productive cough, typically linked to conditions like the common cold or Upper Respiratory Tract Infections. The research examined outcomes related to physical discomfort over defined time intervals.

Findings describe patterns observed in the studies related to measured changes in the count of cough events over 24 hours, often comparing the active substance against a placebo. Research highlights changes measured during the study period by exploring how measured symptom scores varied over time. Evidence contributes to understanding symptom patterns.

Objective Measurement vs. Subjective Patient Reports

Studies explored two distinct ways of assessing the medicine’s activity: objective measurement (laboratory settings where research examined the body’s cough reflex sensitivity) and subjective assessment (patient-reported experiences using diaries or severity scales).

Research describes patterns related to changes in the cough reflex threshold when tested in a controlled, objective setting. However, when compared with placebo, the findings regarding patient-reported outcomes describing perceived discomfort in daily life were often mixed. This observation highlights a noted difference in research findings between objective physiological measures and patient-reported outcomes.

Duration of Study and Long-Term Follow-up

Due to this focus on acute conditions, follow-up durations were limited in many key studies. There is limited information for long-term outcomes or durability of effect, as the research is highly focused on conditions associated with acute or disruptive episodes. Therefore, long-term effects are not fully established.

Evidence in Special Populations

Research included healthy adults and pediatric patients (children aged 6–11 years) with cough due to the common cold. The safety and activity of the medicine was evaluated in very young children (under six years of age) with limited systematic research; data for this subgroup remain insufficient. For this reason, specific official guidance regarding use in this youngest age group is based on the limited data available.

Study Limitations and Research Gaps

Studies conducted during periods of increased symptom activity are highly susceptible to a high placebo response. Due to the high placebo response, the certainty remains low regarding the clinical significance of some measured changes, and continued research is ongoing.

Key Studies & References

  1. Cough (acute): antimicrobial prescribing (NG120) - NICE Guideline
  2. Acute Cough Study In Children (Dextromethorphan Hydrobromide) - ClinicalTrials.gov (NCT01257542)
  3. Dextromethorphan: MedlinePlus Drug Information (Authoritative Patient Information)

Frequently Asked Questions (FAQ)

Common questions about Mugotussol (FAQ)


Q: What is the main difference between Mugotussol and other popular cough medicines?

A: Official information indicates that the active ingredient in Mugotussol is a non-opioid cough suppressant with a central action on the brain's cough center. This mechanism is how official descriptions distinguish it from other drug classes, such as expectorants, which are designed to help clear mucus, or decongestants.


Q: If I have a chronic medical condition, can I still use Mugotussol?

A: Regulatory warnings advise that consulting a healthcare professional is recommended before use if you have certain existing conditions. These conditions include chronic diseases such as heart disease, high blood pressure, thyroid disease, or diabetes. Official product information also advises against use for chronic coughs, such as those related to asthma or chronic bronchitis, without specific medical advice.


Q: How long does it usually take before Mugotussol starts working?

A: Dextromethorphan, the active ingredient, is generally absorbed quickly after use. The exact time to action can vary between individuals. However, its total duration of action in the body is generally cited in product information as lasting 3 to 8 hours.


Q: Can I take Mugotussol if I am already taking over-the-counter pain relievers?

A: Official guidance indicates that its active ingredient can typically be used with common over-the-counter pain relievers like acetaminophen or ibuprofen. However, consumers are cautioned to carefully check the labels of other combination cold products to avoid unintentionally taking duplicate doses of pain relievers.


Q: Is it true that Mugotussol can interact with blood pressure medications?

A: Official warnings advise consulting a health professional if you have high blood pressure or if you are taking drugs that inhibit the CYP2D6 enzyme. Certain blood pressure medications may be CYP2D6 inhibitors. This profile signals a potential risk that is described as requiring professional consultation.


Q: Are there different strengths of Mugotussol available?

A: Official product information shows that the active ingredient is marketed in various concentrations depending on the specific product type (e.g., syrup versus tablet). Regulatory labels define different doses, such as 18 mg and 30 mg per dose, reflecting the availability of various strengths and formulations.


Q: Is Mugotussol considered safe for use in older adults?

A: According to official regulatory documents, the normal adult dose is generally acceptable for use in the elderly. However, caution may be advised because older patients are documented as being more susceptible to anticholinergic adverse effects, such as mental confusion.


Q: What specific ingredients are listed under 'inactive ingredients' in Mugotussol?

A: The inactive ingredients vary significantly by the specific dosage form (tablet, syrup, etc.). However, official regulatory labels frequently list common components such as glycerin, propylene glycol, sorbitol, and sweeteners. For certain formulations, warnings exist regarding ingredients like aspartame, which is relevant for individuals with Phenylketonuria (PKU).


Q: What should I do if I think I'm having an interaction with Mugotussol?

A: The official guidance emphasizes immediate professional action for safety concerns. If you experience serious symptoms like a severe rash, it is described that contacting a healthcare professional is important. For a severe drug-drug interaction or suspected overdose, official health resources indicate that contacting a local emergency number or a Poison Control Center is the required action.


Q: Is Mugotussol known to cause any long-term dependency?

A: Official regulatory safety documents confirm that cases of dextromethorphan abuse and dependence have been reported. Official documents state that caution may be advised for adolescents and for patients who have a history of substance abuse or dependence.


Q: Are there any specific foods or drinks that should be avoided when using Mugotussol?

A: Official documents state that the use of alcohol is advised against while using this medicine. This is because alcohol is a Central Nervous System (CNS) depressant and is documented to worsen side effects such as drowsiness, dizziness, and slowed reactions.


Q: How quickly is Mugotussol eliminated from the body?

A: The official product information addresses this through its pharmacokinetics profile. The plasma elimination half-life (the time it takes for half the drug to be eliminated) is typically around 2 to 4 hours in most people. However, in individuals who are poor metabolizers of the drug, this elimination time can be significantly prolonged.


Q: Can Mugotussol be taken with common vitamins or supplements?

A: Official safety guidance advises that informing a healthcare professional about all products being taken is necessary. This includes prescription and nonprescription medications, common vitamins, nutritional supplements, and herbal products, so that monitoring for potential side effects can be ensured.


Q: What is the difference between Mugotussol and a regular throat lozenge?

A: Mugotussol's active ingredient is a systemic cough suppressant, meaning it is absorbed into the body and works centrally on the cough reflex in the brain. A regular throat lozenge, by contrast, is described as a locally acting demulcent or anesthetic that works only to soothe irritation in the throat.

How should Mugotussol be stored and disposed of?

Official Storage and Disposal Requirements

This section outlines the officially documented storage and disposal requirements for Mugotussol, based on regulatory labeling for its active ingredients.

Requirement Area Official Instruction
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F).
Protection Protect the product from light.
Container Integrity Keep the container tightly closed and do not use if the tamper-evident seal is broken.
Child Safety Keep Mugotussol out of the reach of children.
Disposal Specific disposal instructions should follow local regulations for unused or expired medicines.

Regulatory documents define the storage profile by mandating a specific temperature range for stability and requiring protection from light and the use of a tightly closed container. It is a mandatory requirement to store the medicine away from children to prevent accidental ingestion.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Mugotussol found in:

A-Z Index: